Overview
NCEL market data
Price History
NCEL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$12.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.90 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.83 – $28.03 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $20.3 · P/B 4.65.
Company news
NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment TechnologyBenzinga · Jul 15, 2026, 1:01 PM
Laidlaw & Co. Initiates Coverage On NewcelX with Buy Rating, Announces Price Target of $23Benzinga · Jul 13, 2026, 11:28 AM
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed StrategyBenzinga · Jul 1, 2026, 1:40 PM
NewcelX Announces Publication Of Peer-Reviewed Study On The Potential Of AstroRx, A Human Embryonic Stem Cells-Derived Astrocyte Therapy, In The Journal Stem Cell ReportsBenzinga · Jun 15, 2026, 12:40 PM
EXCLUSIVE: NewcelX Submits Pre-IND Briefing Package To FDA for Type 1 Diabetes Therapy NCEL-101; Schedules Type B Pre-IND Meeting With FDA For Late June (Benzinga · May 27, 2026, 11:32 AM
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND SubmissionBenzinga · May 27, 2026, 11:31 AM